LMN-201 for Prevention of C. Difficile Infection Recurrence | MicrobiomeTrials← Back to trialsNCT05330182
LMN-201 for Prevention of C. Difficile Infection Recurrence
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2024-08-29Est. Completion: 2026-08-31
Enrollment target: 375 participants Locations- Kaiser Permanente, Escondido, California, United States
- Gastroenterology Center of Connecticut, Hamden, Connecticut, United States
- University of South Florida, Tampa, Florida, United States
- Metro Infectious Disease Consultants, LLC, Burr Ridge, Illinois, United States
- Baptist Health Research, Lexington, Kentucky, United States
- Henry Ford Health System, Detroit, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Mayo Clinic - Rochester, Rochester, Minnesota, United States
- Weill Cornell Medicine, New York, New York, United States
- IMA Clinical Research, Mount Airy, North Carolina, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Clinical Alliance for Infectious Diseases - Infectious Diseases, LLC, Annandale, Virginia, United States
- University of Virginia School of Medicine, Charlottesville, Virginia, United States
- Kaiser Permanente-Mid Atlantic, Springfield, Virginia, United States
- UW Health University Hospital, Madison, Wisconsin, United States
Other microbiome trials you might be interested in
Clostridium Difficile Infection
This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose …
Knoxville, United StatesEst. completion Aug 22, 2028
Neutropenia, Febrile
The goal of this clinical trial is to compare a short course of antibiotics in patients in whom no bacterial infection i…
Leuven, BelgiumCompleted Mar 8, 2026
Phase 4
Recruiting
Blood Stream InfectionsVentilator Associated PneumoniaHealthcare Associated InfectionCarbapenem-Resistant Enterobacteriaceae InfectionHospital-acquired Pneumonia
RAPID is an investigator initiated Phase 4, multinational, multicentre, open-label, randomised controlled superiority tr…
Vellore, IndiaEst. completion Oct 31, 2027